文献速递血栓与止血

凝血因子V是外源性凝血途径的抗凝物并调节血友病A的凝血酶生成

Factor V is an anticoagulant of the extrinsic pathway of coagulation and modifier of thrombin generation in hemophilia A.
PubMed 文献 · Blood · 2026-07-24

研究探讨凝血因子V(FV)如何限制组织因子(TF)启动的凝血,假设前辅因子FV下调TF:FVIIa对因子X(FX)的激活且不依赖TFPIα,并在血友病中尤为重要。在FV/FVIII免疫去除血浆和合成血浆中滴定FV,测量凝血酶生成,并在脂质体上测量FX激活。结果显示FV通过膜依赖机制抑制TF:FVIIa激活FX,在血友病A血浆中较高FV与凝血酶生成降低相关。

要点

  • FV在生理浓度下可抑制TF:FVIIa对FX的激活约80%。
  • 在缺乏TFPIα时,FV对凝血酶生成的抑制在低FVIII条件下更明显。
  • 血友病A血浆中较高FV与凝血酶生成峰值降低独立相关。

核心结论

  • FV是内源性抗凝物,通过限制TF:FVIIa激活FX来抑制TF启动的凝血。

研究设计与样本

  • 在FV/FVIII免疫去除血浆和合成血浆中滴定FV,并去除、阻断或重新加入TFPIα,测量凝血酶生成。
  • 在含磷脂酰丝氨酸或无磷脂酰丝氨酸的脂质体上,用抗FV轻链和C2结构域抗体测量TF:FVIIa对FX的激活。
  • 在血友病A患者血浆中分析FV和TFPIα水平对凝血酶生成的影响。

主要发现

  • 在缺乏TFPIα的TF启动凝血中,凝血酶生成在2 nM FV时达峰值,随FV升高而下降。
  • 在20 nM FV(正常浓度)时,峰值凝血酶和凝血酶生成速率降低达50-80%,低FVIII时效应更大。
  • 在纯化TF:FVIIa试验中,生理浓度FV使FX激活降低约80%,并抑制TF表达成纤维细胞上的FX激活。
  • 增加磷脂酰丝氨酸含量增强FX激活并增加FV敏感组分,阻断FV轻链或C2结构域部分缓解抑制。
  • 在血友病A血浆中,较高FV与较长滞后时间和达峰时间、较低峰值凝血酶相关,独立于TFPIα。

临床怎么用

  • FV水平可能影响血友病A患者的凝血酶生成和出血/血栓风险,需进一步临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Factor V (FV) links procoagulant amplification to anticoagulant feedback, but how FV limits tissue factor-initiated coagulation are not fully defined. We hypothesized that procofactor FV downregulates factor X (FX) activation by tissue factor:factor VIIa (TF:FVIIa), independently of tissue factor pathway inhibitor α (TFPIα), and that this mechanism is especially important in hemophilia. Thrombin generation was measured in FV/FVIII‑immunodepleted plasma and synthetic plasma while titrating FV, with TFPIα removed, blocked, or re-added. TF:FVIIa activation of FX was measured on phosphatidylserine‑containing or phosphatidylserine‑free liposomes with antibodies against the FV light chain and C2 domain. FV and TFPIα levels modulated thrombin generation in plasma from people with hemophilia A. In TF‑initiated coagulation lacking TFPIα, thrombin generation peaked at 2 nM FV and decreased as FV increased; at 20 nM FV (normal concentration), peak thrombin and thrombin generation rate were reduced by up to 50-80%, with larger effects at low FVIII. In purified TF:FVIIa assays, FV reduced FX activation by ~80% at physiologic concentration and inhibited FX activation on TF-expressing fibroblasts. Increasing PS content enhanced FX activation and increased the FV-sensitive component, while blocking the FV light chain or C2 domain partially relieved inhibition. In hemophilia A plasma, higher FV was associated with longer lag time and time-to-peak, and lower peak thrombin independent of TFPIα. Thus, FV is an endogenous anticoagulant that inhibits TF-initiated coagulation by limiting FX activation by TF:FVIIa through a membrane-dependent mechanism. This mechanism refines models of coagulation initiation and may help explain how FV variation contributes to bleeding and thrombosis.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Jewell M, Baird CH, Thornhill D, et al. Factor V is an anticoagulant of the extrinsic pathway of coagulation and modifier of thrombin generation in hemophilia A. Blood. 2026. PMID: 42498286. doi:10.1182/blood.2025032705

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。